Landscape → CNS

Multiple Sclerosis

767 clinical trials

298 active

767 total (since 2015)

Phase 1 Active

221 total

138

Phase 2 Active

313 total

Phase 3 Active

188 total

Phase 4 Active

130 total

Top Sponsors (Industry)

Sorted by active Active Done Failed

Roche 17 12 2

Novartis 14 16 2

Sanofi 5 13 1

TG Therapeutics, Inc. 4 4 0

Immunic AG 4 0 0

Bristol-Myers Squibb 3 3 2

Zenas BioPharma (USA), LLC 3 0 0

Tiziana Life Sciences LTD 2 0 1

GV20 Therapeutics 2 0 0

Hansoh BioMedical R&D Company 2 0 0

Biogen 1 18 13

Biocad 1 6 0

Theravance Biopharma 1 1 1

AstraZeneca 1 1 0

Hope Biosciences Research Foundation 1 1 0

NCT07446894 RECRUITING

MSA-01 in Multiple System Atrophy

Tokyo University n=140

NCT06346197 RECRUITING

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Centre Leon Berard n=132

NCT05877963 RECRUITING

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

TG Therapeutics, Inc. n=800

NCT07210463 RECRUITING

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

Merz Aesthetics GmbH n=300

NCT06700343 RECRUITING

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Amgen n=444

NCT04130997 ACTIVE NOT RECRUITING

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

TG Therapeutics, Inc. n=1,100

NCT07211633 RECRUITING

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

TG Therapeutics, Inc. n=360

NCT07220252 NOT YET RECRUITING

Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

TG Therapeutics, Inc. n=240

NCT07325292 RECRUITING

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

Sanofi n=160

NCT06141486 RECRUITING

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Sanofi n=900

NCT05134441 ACTIVE NOT RECRUITING

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Immunic AG n=1,121

NCT05201638 ACTIVE NOT RECRUITING

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Immunic AG n=1,100

NCT04035005 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Hoffmann-La Roche n=1,013

NCT04926818 ACTIVE NOT RECRUITING

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Novartis Pharmaceuticals n=129

NCT07225504 RECRUITING

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Novartis Pharmaceuticals n=1,275

NCT06846281 RECRUITING

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Novartis Pharmaceuticals n=360

NCT03295383 RECRUITING

Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid

University Hospital, Rouen n=130

NCT06675955 RECRUITING

An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

Hoffmann-La Roche n=500

NCT04544436 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Hoffmann-La Roche n=864

NCT04586010 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Hoffmann-La Roche n=746

NCT06372145 ACTIVE NOT RECRUITING

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Sanofi n=2,500

NCT06869785 ACTIVE NOT RECRUITING

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Novartis Pharmaceuticals n=196

NCT06408259 RECRUITING

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Celgene n=194

NCT06847724 RECRUITING

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

Sandoz n=175

NCT05147220 ACTIVE NOT RECRUITING

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Novartis Pharmaceuticals n=1,001

NCT05156281 ACTIVE NOT RECRUITING

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Novartis Pharmaceuticals n=1,011

NCT05758831 RECRUITING

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

Rennes University Hospital n=386

NCT05269004 ACTIVE NOT RECRUITING

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Hoffmann-La Roche n=1,300

NCT05123703 ACTIVE NOT RECRUITING

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Hoffmann-La Roche n=188

NCT03523858 ACTIVE NOT RECRUITING

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Hoffmann-La Roche n=927

NCT06141473 RECRUITING

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Sanofi n=1,600

NCT03650114 ACTIVE NOT RECRUITING

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Novartis Pharmaceuticals n=1,882

NCT05999604 RECRUITING

Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

Fondation Ophtalmologique Adolphe de Rothschild n=244

NCT07299019 NOT YET RECRUITING

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Zenas BioPharma (USA), LLC n=990

NCT04047628 RECRUITING

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

National Institute of Allergy and Infectious Diseases (NIAID) n=156

NCT07321093 RECRUITING

A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

Biocad n=292

NCT04544449 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Hoffmann-La Roche n=985

NCT06791512 RECRUITING

mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC

Jun Huang n=166

NCT04586023 ACTIVE NOT RECRUITING

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Hoffmann-La Roche n=751

NCT04548999 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Hoffmann-La Roche n=769

NCT05008731 ACTIVE NOT RECRUITING

Cyclops Syndrome After Anterior Cruciate Ligament Reconstruction

GCS Ramsay Santé pour l'Enseignement et la Recherche n=132

NCT07067463 RECRUITING

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

Zenas BioPharma (USA), LLC n=705

NCT07122193 RECRUITING

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

Merz North America, Inc. n=300

NCT07189325 NOT YET RECRUITING

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

University Hospital, Montpellier n=250

NCT05441488 ACTIVE NOT RECRUITING

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

AB Science n=800

NCT03958877 ACTIVE NOT RECRUITING

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Biogen n=152

NCT04695080 ACTIVE NOT RECRUITING

ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis

Queen Mary University of London n=204

NCT06966804 RECRUITING

Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms

Penang Hospital, Malaysia n=150

NCT05696717 ACTIVE NOT RECRUITING

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

Theravance Biopharma n=102

NCT06771492 RECRUITING

Efficacy of Antibiotic Treatment for Patients With Chronic Low Back Pain and Modic Type I Changes - Randomized Placebo-controlled Trial

Bart Koes n=204

NCT04688788 ACTIVE NOT RECRUITING

Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

Rigshospitalet, Denmark n=600

NCT04578639 ACTIVE NOT RECRUITING

Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease

Haukeland University Hospital n=214

NCT03477500 ACTIVE NOT RECRUITING

Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)

Haukeland University Hospital n=100

NCT05955001 RECRUITING

Efficacy of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Endoscopic Enucleation of Prostate

Mansoura University n=110

NCT05834478 RECRUITING

Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

Emory University n=103

NCT06120049 RECRUITING

[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD

prof. dr. Koen Van Laere n=113

NCT06663189 NOT YET RECRUITING

Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)

University Hospital, Strasbourg, France n=200

NCT06526728 RECRUITING

Hyperbaric Oxygen Therapy in HAMstring Injury (HOTHAM) Trial

JL Tol n=50

NCT05338450 RECRUITING

Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis

Amsterdam UMC, location VUmc n=80

NCT06248710 RECRUITING

Dog Presence and Oxytocin on Trust Towards Therapists

Dr. Karin Hediger n=176

NCT02676739 ACTIVE NOT RECRUITING

Adderall XR and Cognitive Impairment in MS

Sarah Morrow n=180

NCT05906992 RECRUITING

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Celltrion n=512

NCT05210621 ACTIVE NOT RECRUITING

LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB

Centre Hospitalier Universitaire de Nice n=72

NCT03408080 ACTIVE NOT RECRUITING

Open Pilot Trial of BHV-4157

University of California, Los Angeles n=24

NCT06087757 RECRUITING

Clemastine Treatment in Individuals With Williams Syndrome

Sheba Medical Center n=30

NCT06315699 RECRUITING

Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome

Qilu Hospital of Shandong University n=50

NCT05890742 RECRUITING

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Innovent Biologics (Suzhou) Co. Ltd. n=360

NCT03653273 RECRUITING

Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)

Rennes University Hospital n=250

NCT05961644 RECRUITING

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

Institute of Psychiatry and Neurology, Warsaw n=188

NCT05834855 RECRUITING

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

Amsterdam UMC, location VUmc n=200

NCT04807010 NOT YET RECRUITING

PROARTE -PROstate ARTery to Reduce the Symptoms of Benign Prostatic Hyperplasia

Society of Interventional Radiology Foundation n=108

NCT04788615 COMPLETED

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Novartis Pharmaceuticals n=185

NCT04510220 COMPLETED

9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis

Brigham and Women's Hospital n=10

NCT04486716 COMPLETED

A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

Novartis Pharmaceuticals n=111

NCT04458051 COMPLETED

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

Sanofi n=767

NCT04090957 COMPLETED

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)

Estetra n=1,015

NCT05979844 COMPLETED

MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD

Dr. Leslie Morland n=16

NCT03368664 TERMINATED

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

Genzyme, a Sanofi Company n=16

NCT05265728 TERMINATED

A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Biogen n=21

NCT03599245 COMPLETED

This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Hoffmann-La Roche n=1,055

NCT04353492 COMPLETED

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

Novartis Pharmaceuticals n=562

NCT05083923 COMPLETED

A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

Biogen n=136

NCT05232825 COMPLETED

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

Hoffmann-La Roche n=236

NCT04425473 COMPLETED

Esketamine and Perioperative Depressive Symptoms

Beijing Tiantan Hospital n=435

NCT04410978 COMPLETED

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

Sanofi n=974

NCT04410991 COMPLETED

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

Sanofi n=899

NCT04411641 COMPLETED

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Sanofi n=1,131

NCT03232073 COMPLETED

Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

Actelion n=877

NCT04338022 TERMINATED

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany n=1,124

NCT04140305 TERMINATED

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

Celgene n=188

NCT03365687 COMPLETED

Vitamin D In the Prevention of Viral-induced Asthma in Preschoolers

Professor Francine Ducharme n=323

NCT06987851 COMPLETED

An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD

Biocad n=44

NCT04925557 TERMINATED

Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

State University of New York at Buffalo n=8

NCT02425644 COMPLETED

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

Actelion n=1,133

NCT04338061 TERMINATED

Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany n=1,166

NCT05028634 COMPLETED

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Celgene n=63

NCT04209543 COMPLETED

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

Estetra n=1,570

NCT03085810 TERMINATED

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Hoffmann-La Roche n=1,225

NCT03575052 COMPLETED

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

ACADIA Pharmaceuticals Inc. n=784

NCT03623321 COMPLETED

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

ACADIA Pharmaceuticals Inc. n=595

NCT04121403 COMPLETED

Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)

Oslo University Hospital n=267

NCT04984278 TERMINATED

Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

Jazz Pharmaceuticals n=56

NCT02220829 COMPLETED

Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy

Sir Mortimer B. Davis - Jewish General Hospital n=148

NCT05749939 COMPLETED

Acceptance Commitment Therapy for Caregivers of People with Memory Loss

Utah State University n=121

NCT05385744 COMPLETED

An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis

Biocad n=336

NCT05033886 COMPLETED

A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause

Astellas Pharma Global Development, Inc. n=453

NCT06402487 COMPLETED

Propionic Acid in Multiple Sclerosis

Salzburger Landeskliniken n=101

NCT03387670 COMPLETED

Multiple Sclerosis-Simvastatin Trial 2

University College, London n=964

NCT03283397 TERMINATED

A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS

Bosnalijek D.D n=301

NCT04993729 COMPLETED

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Tasly Pharmaceuticals, Inc. n=853

NCT03623243 COMPLETED

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

Novartis Pharmaceuticals n=185

NCT03689972 COMPLETED

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Biogen n=585

NCT02688985 COMPLETED

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

Genentech, Inc. n=131

NCT04203498 TERMINATED

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

Jazz Pharmaceuticals n=139

NCT06227676 COMPLETED

Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25

Cornell University n=12

NCT02545868 COMPLETED

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Hoffmann-La Roche n=102

NCT04175834 COMPLETED

Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab

Providence Health & Services n=19

NCT02576717 COMPLETED

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

Celgene n=2,494

NCT06231433 COMPLETED

Effects of Fractional CO2 Laser Treatment on Vaginal Symptoms and Sexual Dysfunction in Women With Systemic Sclerosis

IRCCS San Raffaele n=16

NCT04626921 COMPLETED

A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

Clene Nanomedicine n=55

NCT04121221 COMPLETED

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

Mapi Pharma Ltd. n=1,016

NCT03824938 COMPLETED

Aspirin for Exercise in Multiple Sclerosis (ASPIRE)

Columbia University n=60

NCT04193527 COMPLETED

A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients

GE Healthcare n=172

NCT02841215 COMPLETED

Efficacy Study Between Two Different Dosages of an Antiparasitic in Patients With Crusted Scabies

Assistance Publique - Hôpitaux de Paris n=133

NCT04657666 COMPLETED

Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

Jazz Pharmaceuticals n=68

NCT04115488 COMPLETED

Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®

Polpharma Biologics S.A. n=265

NCT03870763 TERMINATED

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Biogen n=11

NCT03383666 TERMINATED

A Study Evaluating the Safety and Effectiveness of the PulseRider® Aneurysm Neck Reconstruction Device Used in Conjunction With Endovascular Coil Embolization in the Treatment of Wide-Neck Bifurcation Intracranial Aneurysm

Pulsar Vascular n=21

NCT05886829 COMPLETED

Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III

Dr. Ferrer BioPharma n=157

NCT05128344 WITHDRAWN

A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms

Amzell

NCT03229551 COMPLETED

Xylitol for Chronic Sinusitis

Ochsner Health System n=1

NCT04291456 TERMINATED

Minocycline in MS: Confirmation of Benefit

University of Calgary n=9

NCT05449405 COMPLETED

Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I

Dr. Ferrer BioPharma n=101

NCT02587195 COMPLETED

A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period

Centre Hospitalier Universitaire de Nice n=5

NCT03122652 COMPLETED

Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome

Centre Hospitalier Universitaire de Nice n=125

NCT02727907 COMPLETED

Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Biocad n=163

NCT03829657 TERMINATED

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Theravance Biopharma n=203

NCT05242133 COMPLETED

Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

Cinnagen n=168

NCT04966338 COMPLETED

Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis

Cinnagen n=170

NCT03774407 COMPLETED

Vaginal Estriol in Multiple Sclerosis

Texas Tech University Health Sciences Center n=21

NCT02953548 COMPLETED

Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)

Jazz Pharmaceuticals n=9

NCT02954887 COMPLETED

Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)

Jazz Pharmaceuticals n=9

NCT03319732 COMPLETED

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS

RVL Pharmaceuticals, Inc. n=323

NCT04595045 COMPLETED

Botulinum Toxin in Patients With Spastic Lower Limb Paresis Associated With Multiple Sclerosis

Aránzazu Vázquez Doce n=84

NCT02634307 COMPLETED

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

Biogen n=1,057

NCT03290131 COMPLETED

A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS

RVL Pharmaceuticals, Inc. n=536

NCT02869425 WITHDRAWN

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

RVL Pharmaceuticals, Inc.

NCT02861014 COMPLETED

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Hoffmann-La Roche n=681

NCT03567057 COMPLETED

A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Adamas Pharmaceuticals, Inc. n=424

NCT05172115 TERMINATED

Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE

Rajaie Cardiovascular Medical and Research Center n=94

NCT03436199 COMPLETED

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

Adamas Pharmaceuticals, Inc. n=558

NCT03277261 COMPLETED

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

TG Therapeutics, Inc. n=549

NCT03277248 COMPLETED

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

TG Therapeutics, Inc. n=545

NCT03524339 COMPLETED

Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery

University Hospitals Cleveland Medical Center n=132

NCT02746744 COMPLETED

RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.

Anders Svenningsson n=200

NCT02792218 COMPLETED

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

Novartis Pharmaceuticals n=930

NCT02744222 COMPLETED

Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis

Biocad n=399

NCT04032171 TERMINATED

Study of Evobrutinib in Participants With RMS

EMD Serono Research & Development Institute, Inc. n=1

NCT04032158 TERMINATED

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

EMD Serono Research & Development Institute, Inc. n=3

NCT02980042 COMPLETED

Safety of Switching From Rituximab to Ocrelizumab in MS Patients

University of Colorado, Denver n=200

NCT02907177 TERMINATED

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

Actelion n=136

NCT03756974 COMPLETED

BX-1 in Spasticity Due to Multiple Sclerosis

Bionorica SE n=397

NCT03652948 COMPLETED

Meru Health Ascend Mobile Intervention for Depression in Middle Aged and Older Adults

Palo Alto Veterans Institute for Research n=70

NCT03342638 TERMINATED

Maximizing Outcome of Multiple Sclerosis Transplantation

Northwestern University n=66

NCT02936037 TERMINATED

Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)

MedDay Pharmaceuticals SA n=642

NCT03185065 COMPLETED

Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis

Johns Hopkins University n=141

NCT03093324 COMPLETED

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

Biogen n=506

NCT03606460 COMPLETED

A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)

Genentech, Inc. n=141

NCT02637856 COMPLETED

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Genentech, Inc. n=608

NCT02555215 COMPLETED

Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Biogen n=20

NCT02299115 WITHDRAWN

Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms

The Hospital for Sick Children

NCT02881567 TERMINATED

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

Biogen n=41

NCT02315872 COMPLETED

ACTH for Fatigue in Multiple Sclerosis Patients

Providence Health & Services n=8

NCT02672189 COMPLETED

Internet-based Cognitive Behavioral Therapy for Breast Cancer Patients With Climacteric Symptoms

The Netherlands Cancer Institute n=254

NCT02965430 COMPLETED

PERFORMANCE STUDY OF THE AL-SENSE

Common Sense n=352

NCT02972268 COMPLETED

Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH

Jeil Pharmaceutical Co., Ltd. n=780

NCT02525874 COMPLETED

Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Biogen n=218

NCT02838043 COMPLETED

The Efficacy, Safety, and Tolerability of Probiotics on the Mood and Cognition of Depressed Patients

Queen's University n=10

NCT03315923 COMPLETED

Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients

Isfahan University of Medical Sciences n=84

NCT02939079 COMPLETED

Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients

Isfahan University of Medical Sciences n=50

NCT03713359 COMPLETED

Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (Phase III)

Center for Research and Production of Vaccines and Biologicals, Vietnam n=756

NCT03172741 WITHDRAWN

The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis

Colorado State University

NCT02428231 TERMINATED

Tecfidera Slow-Titration Study

Biogen n=62

NCT02430532 TERMINATED

BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis

Biogen n=58

NCT02597634 COMPLETED

Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)

Strategic Science & Technologies, LLC n=156

NCT02695381 COMPLETED

Etodolac-lidocaine Patch in Subjects Experiencing Acute Delayed Onset Muscle Soreness

MEDRx USA, Inc. n=100

NCT02391571 COMPLETED

A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects

Elite Laboratories, Inc n=26

NCT02428218 WITHDRAWN

Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Biogen

NCT03213652 ACTIVE NOT RECRUITING

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

NCT03210714 ACTIVE NOT RECRUITING

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

NCT02867592 ACTIVE NOT RECRUITING

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

NCT07282574 RECRUITING

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

Hoffmann-La Roche

NCT07437547 RECRUITING

BPC 157 for Acute Hamstring Muscle Strain Repair

Hudson Biotech

NCT04969887 ACTIVE NOT RECRUITING

Combination Immunotherapy in Rare Cancers Under InvesTigation

Olivia Newton-John Cancer Research Institute

NCT06957691 RECRUITING

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Shehzad Basaria, M.D.

NCT06948331 NOT YET RECRUITING

RADA16 for Aquablation Day Case

NYU Langone Health

NCT06782490 RECRUITING

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Celgene

NCT04851119 RECRUITING

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

NCT07144293 RECRUITING

Improving Physical Ability and Cellular Senescence Elimination in HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04322318 RECRUITING

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Children's Oncology Group

NCT06617793 RECRUITING

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

Novartis Pharmaceuticals

NCT04530318 ACTIVE NOT RECRUITING

Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis

Judit Pich

NCT03109288 RECRUITING

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03155620 ACTIVE NOT RECRUITING

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

NCT07399769 RECRUITING

Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors

Shenzhen University General Hospital

NCT07161258 RECRUITING

A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)

Hoffmann-La Roche

NCT04901702 RECRUITING

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

St. Jude Children's Research Hospital

NCT05066308 RECRUITING

Cannabidiol for Reduction of Brain Neuroinflammation

Massachusetts General Hospital

NCT05119569 ACTIVE NOT RECRUITING

A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)

Hoffmann-La Roche

NCT07074886 RECRUITING

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Hoffmann-La Roche

NCT03207464 RECRUITING

Molecular Imaging of NET Using [C-11]MRB-PET in MS

Brigham and Women's Hospital

NCT04195555 ACTIVE NOT RECRUITING

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

NCT02649985 RECRUITING

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

Brigham and Women's Hospital

NCT07366931 NOT YET RECRUITING

The Effect of Daily Supplementation With Humiome® Post LB on Gastrointestinal Symptoms in Female Athletes

Liverpool John Moores University

NCT04968990 RECRUITING

Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation

St. Jude Children's Research Hospital

NCT06261489 ACTIVE NOT RECRUITING

Cannabis (THC vs. CBD) in Multiple Sclerosis

University of Calgary

NCT05418010 RECRUITING

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Queen Mary University of London

NCT04795661 ACTIVE NOT RECRUITING

Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.

Centre Leon Berard

NCT07020715 NOT YET RECRUITING

A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis

University Hospital, Antwerp

NCT07310914 NOT YET RECRUITING

Implementation of an Advanced Telerehabilitation Solution for People With Multiple Sclerosis

Danish Multiple Sclerosis Hospitals

NCT06991114 RECRUITING

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Artiva Biotherapeutics, Inc.

NCT04075266 ACTIVE NOT RECRUITING

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

Hoffmann-La Roche

NCT06735248 RECRUITING

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

ModernaTX, Inc.

NCT06511908 RECRUITING

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

National Institute of Mental Health (NIMH)

NCT05378100 RECRUITING

Ketamine for Multiple Sclerosis Fatigue

Johns Hopkins University

NCT06220669 RECRUITING

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

Eli Lilly and Company

NCT06944145 RECRUITING

New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

Beth Israel Deaconess Medical Center

NCT03607890 RECRUITING

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT07263607 NOT YET RECRUITING

A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Taurine as an Adjunctive Therapy in Multiple Sclerosis

Sichuan Academy of Medical Sciences

NCT04284774 ACTIVE NOT RECRUITING

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

NCT04320888 ACTIVE NOT RECRUITING

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

NCT07070518 RECRUITING

Study of GV20-0251 in Participants With Solid Tumor Malignancies

GV20 Therapeutics

NCT03213704 ACTIVE NOT RECRUITING

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

NCT03698994 ACTIVE NOT RECRUITING

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

NCT07160647 ACTIVE NOT RECRUITING

The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)

Sir Run Run Shaw Hospital

NCT06850103 RECRUITING

SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases

First Affiliated Hospital of Zhejiang University

NCT05985161 RECRUITING

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Memorial Sloan Kettering Cancer Center

NCT06463743 RECRUITING

Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)

State University of New York at Buffalo

NCT07178431 NOT YET RECRUITING

MB-CART2019.1 in Refractory Multiple Sclerosis

Miltenyi Biomedicine GmbH

NCT06675864 RECRUITING

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

Novartis Pharmaceuticals

NCT06800404 ACTIVE NOT RECRUITING

"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"

Hope Biosciences Research Foundation

NCT06564311 ACTIVE NOT RECRUITING

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

Zenas BioPharma (USA), LLC

NCT04267926 ACTIVE NOT RECRUITING

MitoQ for Fatigue in Multiple Sclerosis (MS)

VA Office of Research and Development

NCT07006805 NOT YET RECRUITING

RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

Cabaletta Bio

NCT07222956 NOT YET RECRUITING

A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

Moein Amin

NCT07221565 ENROLLING BY INVITATION

Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting

Truway Health, Inc.

NCT05957913 ENROLLING BY INVITATION

Effects of Antiviral Therapies on Epstein-Barr Virus Replication

Massachusetts General Hospital

NCT06292923 RECRUITING

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Tiziana Life Sciences LTD

NCT06434571 RECRUITING

Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection

University of Kansas Medical Center

NCT04879628 ACTIVE NOT RECRUITING

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

Sanofi

NCT02784210 RECRUITING

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

National Institute of Neurological Disorders and Stroke (NINDS)

NCT04121468 RECRUITING

A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis

The Hospital for Sick Children

NCT06362369 RECRUITING

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

NCT07042516 RECRUITING

Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).

Tioga Pharmaceuticals

NCT07156682 NOT YET RECRUITING

QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer

Qilu Hospital of Shandong University

NCT07085507 RECRUITING

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients

Vidya Therapeutics Inc

NCT05805839 ENROLLING BY INVITATION

A Study of Imaging in Demyelinating Diseases

Mayo Clinic

NCT06901687 RECRUITING

Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)

NYU Langone Health

NCT06592352 RECRUITING

MODAFIMS: A Trial to Evaluate Predictors of Response to MODAFinil in Patients With Multiple Sclerosis

Clinical Academic Center (2CA-Braga)

NCT07115654 NOT YET RECRUITING

BCMA/CD3 BsAb Therapy for POEMS Syndrome

Institute of Hematology & Blood Diseases Hospital, China

NCT05532943 RECRUITING

Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis

Ever Supreme Bio Technology Co., Ltd.

NCT05269628 RECRUITING

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

Tiffany J. Braley, MD, MS

NCT06428006 RECRUITING

Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis

University of Kansas Medical Center

NCT05086692 RECRUITING

A Beta-only IL-2 ImmunoTherapY Study

Medicenna Therapeutics, Inc.

NCT05286294 ACTIVE NOT RECRUITING

Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders

Oslo University Hospital

NCT03910738 RECRUITING

TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis

University Hospital, Strasbourg, France

NCT05893225 ACTIVE NOT RECRUITING

Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

University Hospital, Antwerp

NCT04006262 ACTIVE NOT RECRUITING

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

GERCOR - Multidisciplinary Oncology Cooperative Group

NCT06170970 RECRUITING

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

Johns Hopkins University

NCT05122559 RECRUITING

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

Emmanuelle Waubant, MD PhD

NCT06890923 RECRUITING

Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Tiziana Life Sciences LTD

NCT05923866 ACTIVE NOT RECRUITING

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Ono Pharmaceutical Co. Ltd

NCT06908031 RECRUITING

SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer

Sixth Affiliated Hospital, Sun Yat-sen University

NCT05806996 RECRUITING

A Study of Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures

Mayo Clinic

NCT06819670 RECRUITING

A Study to Prevent Infantile Spasms Relapse

University of California, Los Angeles

NCT06962657 NOT YET RECRUITING

Mitigating Toxic Impact: The Role of Coenzyme Q10 in Post-Exposure Protection

University of California, San Diego

NCT06961383 NOT YET RECRUITING

Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis

NeuroGenesis Ltd.

NCT06956326 RECRUITING

Illuminating New Paths in the Treatment of Multiple Sclerosis Relapses - Early and Specialized Rehabilitation

Lars Hvid

NCT05395624 RECRUITING

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

Ashvattha Therapeutics, Inc.

NCT06351683 RECRUITING

Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome

Iman Al-Naggar, PhD

NCT06223074 ENROLLING BY INVITATION

Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration

Universidad Nacional Autonoma de Mexico

NCT04053322 ACTIVE NOT RECRUITING

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

UNICANCER

NCT05168384 ACTIVE NOT RECRUITING

Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis

Abu Dhabi Stem Cells Center

NCT05669430 RECRUITING

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

GV20 Therapeutics

NCT05384821 RECRUITING

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

Centre Oscar Lambret

NCT06782724 NOT YET RECRUITING

Psilocybin Therapy for Psychological Distress in Palliative Patients

University Medical Center Groningen

NCT06384976 ACTIVE NOT RECRUITING

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Kyverna Therapeutics

NCT05401032 RECRUITING

Proof-of-concept Study to Evaluate the Safety and Efficacy of Tryptophan in Patients with BPH.

Clinical Academic Center (2CA-Braga)

NCT05092191 RECRUITING

Cannabis as a Complementary Treatment in Multiple Sclerosis

Centre hospitalier de l'Université de Montréal (CHUM)

NCT06722898 NOT YET RECRUITING

Rapid BAC Reduction with Nutraceutical Blend Study

Medical Life Care Planners, LLC

NCT05731726 RECRUITING

Serplulimab Combined with CAPEOX + Celecoxib As Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Zhejiang University

NCT03362294 ACTIVE NOT RECRUITING

Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS

Mapi Pharma Ltd.

NCT03888924 RECRUITING

Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)

S. Andrea Hospital

NCT04787042 RECRUITING

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Simcha IL-18, Inc.

NCT06065670 NOT YET RECRUITING

Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

University of California, San Francisco

NCT06599307 RECRUITING

The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis

Cairo University

NCT06593548 NOT YET RECRUITING

Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer

Fudan University

NCT06580574 RECRUITING

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

Peking University

NCT04742400 ACTIVE NOT RECRUITING

Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

National Institute of Neurological Disorders and Stroke (NINDS)

NCT04636008 RECRUITING

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

West China Hospital

NCT05690503 ACTIVE NOT RECRUITING

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

New York State Psychiatric Institute

NCT05359653 RECRUITING

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

University of California, San Francisco

NCT06448052 ACTIVE NOT RECRUITING

Umbilical Cord Mesenchymal Stem Cell for Aging-related Low-grade Inflammation

Nguyen Ton Ngoc Huynh

NCT06416228 RECRUITING

Beetroot Juice NO Cold Study

Southern Methodist University

NCT06415851 NOT YET RECRUITING

Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab

Zhangfa Song

NCT03514784 RECRUITING

Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder

The University of Texas Health Science Center, Houston

NCT06393673 NOT YET RECRUITING

A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women

Hansoh BioMedical R&D Company

NCT05054140 ACTIVE NOT RECRUITING

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Immunic AG

NCT03846219 ACTIVE NOT RECRUITING

MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)

Immunic AG

NCT06330077 NOT YET RECRUITING

Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis

Assistance Publique - Hôpitaux de Paris

NCT03696953 ACTIVE NOT RECRUITING

The Efficacy of Probiotics to Reduce Antepartum Group B Streptococcus Colonization.

Marquette University

NCT06321081 RECRUITING

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Beijing Hospital

NCT04625153 RECRUITING

RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial

RemeGen Co., Ltd.

NCT05417269 ACTIVE NOT RECRUITING

IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study

Imcyse SA

NCT05740722 RECRUITING

Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis

Haukeland University Hospital

NCT06152523 NOT YET RECRUITING

Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer

Assistance Publique - Hôpitaux de Paris

NCT05970302 RECRUITING

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NCT05815303 RECRUITING

XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NCT03941574 RECRUITING

A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

Shanghai Henlius Biotech

NCT07283705 SUSPENDED

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

M.D. Anderson Cancer Center

NCT05798520 COMPLETED

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Biogen

NCT06841068 WITHDRAWN

Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis

Wake Forest University Health Sciences

NCT05499663 COMPLETED

Title: Leveraging Technology to Address Health Outcomes of Cancer Survivors

University of Maryland, Baltimore

NCT05733611 TERMINATED

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Replimune Inc.

NCT03541200 COMPLETED

Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms

Tanabe Pharma America, Inc.

NCT06322342 COMPLETED

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Reveal Pharmaceuticals Inc.

NCT03993171 COMPLETED

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.

Clene Nanomedicine

NCT05131828 COMPLETED

CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy

Cambridge University Hospitals NHS Foundation Trust

NCT06083753 COMPLETED

Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis

Contineum Therapeutics

NCT03996291 COMPLETED

Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis

Sanofi

NCT03983252 WITHDRAWN

Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis

Brigham and Women's Hospital

NCT05630547 TERMINATED

A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis

Sanofi

NCT02982694 TERMINATED

Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

Vall d'Hebron Institute of Oncology

NCT05116540 COMPLETED

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

Hope Biosciences Research Foundation

NCT03889639 COMPLETED

Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

Sanofi

NCT05000216 TERMINATED

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06715605 WITHDRAWN

A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS

University Hospital, Antwerp

NCT04539002 COMPLETED

Aerobic Exercise for Remyelination in Multiple Sclerosis

Oregon Health and Science University

NCT02907983 WITHDRAWN

Stellate Ganglion Blockade in Post-Menopausal Women

Northwestern University

NCT04979650 COMPLETED

Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis

Mazandaran University of Medical Sciences

NCT02804594 COMPLETED

A Study of Oxidative Pathways in MS Fatigue

University of California, San Francisco

NCT03896217 COMPLETED

Simvastatin in Secondary Progressive Multiple Sclerosis

University College, London

NCT03186326 COMPLETED

Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer

Federation Francophone de Cancerologie Digestive

NCT05005013 COMPLETED

A Teleheath tDCS Approach to Decrease Cannabis Use

NYU Langone Health

NCT03355365 COMPLETED

Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

Tisch Multiple Sclerosis Research Center of New York

NCT04002934 COMPLETED

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

Riley Bove, MD

NCT02975349 TERMINATED

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

EMD Serono Research & Development Institute, Inc.

NCT05183568 COMPLETED

Mindful Self-Compassion (MSC) for Infertility Related Distress

University of Regina

NCT06442137 COMPLETED

A Clinical Trial of Chazhu Xiaozhi Decoction Against Non-alcoholic Fatty Liver Disease

Shanghai Municipal Hospital of Traditional Chinese Medicine

NCT06894940 COMPLETED

Rehabilitative Protocols in Progressive Multiple Sclerosis Treated with Anti CD20 Monoclonal Antibodies

University of Pavia

NCT03161028 COMPLETED

Lipoic Acid for Progressive Multiple Sclerosis (MS)

VA Office of Research and Development

NCT04056897 COMPLETED

Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis

Biocad

NCT05691192 COMPLETED

Cognitive Reserve-building Activities in Multiple Sclerosis

Rigshospitalet, Denmark

NCT05686408 COMPLETED

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

Tonix Pharmaceuticals, Inc.

NCT02865538 COMPLETED

Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms

Bayer

NCT06812585 COMPLETED

The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot Study

German University in Cairo

NCT03213678 COMPLETED

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

NCT03220035 COMPLETED

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

NCT03213665 COMPLETED

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

NCT04791228 WITHDRAWN

A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors

Children's National Research Institute

NCT05302921 COMPLETED

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Children's National Research Institute

NCT04025554 COMPLETED

Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

National Institute of Neurological Disorders and Stroke (NINDS)

NCT04574024 COMPLETED

HFS (High-Fiber Supplement) in MS (Multiple Sclerosis)

Suhayl Dhib-Jalbut, MD

NCT03233204 COMPLETED

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

NCT04480307 COMPLETED

Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis

GeNeuro Innovation SAS

NCT05258630 COMPLETED

Diabetes Homeless Medication Support

Hennepin Healthcare Research Institute

NCT06672094 COMPLETED

A Study to Investigate the Safety and Efficacy of NeuroQ on Cognitive Function in Health Adults with Self-Reported Memory Problems

LifeSeasons Inc.

NCT03526250 COMPLETED

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

NCT05367973 COMPLETED

Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women

Daré Bioscience, Inc.

NCT03976076 TERMINATED

A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients

Bio-Pharm Solutions Co., Ltd.

NCT05325775 COMPLETED

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

Acer Therapeutics Inc.

NCT05612711 WITHDRAWN

Dronabinol for Agitation in Dementia Crossover Trial

Ralph H. Johnson VA Medical Center

NCT03631641 TERMINATED

Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy

John Hays

NCT05062083 TERMINATED

PET Imaging of Cyclooxygenase in Multiple Sclerosis

National Institute of Mental Health (NIMH)

NCT04518852 COMPLETED

TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

Sichuan Cancer Hospital and Research Institute

NCT02624388 TERMINATED

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

University of Virginia

NCT02263729 TERMINATED

Phase 1/2 Prospective Double-Blind Placebo-Controlled Randomized Clinical Trial of Losartan to Treat Grade II & III Hamstring Strains

James J. Irrgang

NCT03696485 WITHDRAWN

Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS

Stem Cell Medicine Ltd.

NCT03652623 COMPLETED

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study

Hektoen Institute for Medical Research

NCT06104683 WITHDRAWN

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

Loxo Oncology, Inc.

NCT03641209 COMPLETED

Extremely Low Gestatonal Age Infants' Paracetamol Study

Outi Aikio

NCT03283826 TERMINATED

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Atara Biotherapeutics

NCT03752307 COMPLETED

Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses

University of New Mexico

NCT05103293 COMPLETED

PTC Guiding Neoadjuvant Treatment in Breast Cancer

Zhejiang Cancer Hospital

NCT03737851 COMPLETED

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

AbbVie

NCT03737812 COMPLETED

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

AbbVie

NCT03799718 COMPLETED

Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS

Brainstorm-Cell Therapeutics

NCT04396496 COMPLETED

Treatment of POEMS Syndrome With Daratumumab

University of Arkansas

NCT04211740 COMPLETED

Phase II Clinical Trial of OCH-NCNP1

National Center of Neurology and Psychiatry, Japan

NCT04437485 COMPLETED

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

Indiana University

NCT05312567 COMPLETED

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

Fervent Pharmaceuticals

NCT02458690 COMPLETED

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

Indiana University

NCT03460756 COMPLETED

A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression

Marinus Pharmaceuticals

NCT03228394 COMPLETED

A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression

Marinus Pharmaceuticals

NCT05207436 COMPLETED

Brief Cognitive Behavioral Conjoint Therapy for PTSD With Adjunctive Intranasal Oxytocin

San Diego Veterans Healthcare System

NCT02462837 TERMINATED

Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement

Southern Illinois University

NCT04079088 WITHDRAWN

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Biogen

NCT05051501 COMPLETED

The Effects of Microbiological Spectrum Changes to Improve Cognitive Health in Aging Population

National Institute of Mental Health, Czech Republic

NCT03423121 COMPLETED

A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis

Johns Hopkins University

NCT02466074 TERMINATED

Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis

The University of Texas Health Science Center, Houston

NCT03166800 TERMINATED

MitoQ for Fatigue in Multiple Sclerosis

Oregon Health and Science University

NCT03536559 TERMINATED

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis

Clene Nanomedicine

NCT02988401 COMPLETED

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

Johns Hopkins University

NCT04767698 TERMINATED

Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis

Johns Hopkins University

NCT03381170 COMPLETED

An Extension of the TG1101-RMS201 Trial

TG Therapeutics, Inc.

NCT05496894 WITHDRAWN

A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

NCT04880577 WITHDRAWN

Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis

Massachusetts General Hospital

NCT04909502 SUSPENDED

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis

Emerald Health Pharmaceuticals

NCT02705755 COMPLETED

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

Theravance Biopharma

NCT03122301 TERMINATED

Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer

Northwestern University

NCT05049161 TERMINATED

A Long-term Extension of Study GNC-401

GeNeuro Innovation SAS

NCT03249714 COMPLETED

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Novartis Pharmaceuticals

NCT03222973 TERMINATED

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

Biogen

NCT04587583 COMPLETED

WeCareAdvisor: A Web-Based Tool to Improve Quality of Life for Military Veterans With Dementia and Their Caregivers

University of Michigan

NCT04971005 TERMINATED

Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial

Universitätsklinikum Hamburg-Eppendorf

NCT02284568 COMPLETED

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

Teva Branded Pharmaceutical Products R&D, Inc.

NCT03549650 TERMINATED

Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms

Sir Mortimer B. Davis - Jewish General Hospital

NCT05026164 COMPLETED

Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity

Canopy Growth Corporation

NCT02452554 COMPLETED

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Children's Oncology Group

NCT03271047 COMPLETED

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Pfizer

NCT02291432 COMPLETED

Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery

Cook MyoSite

NCT03560739 COMPLETED

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

Novartis Pharmaceuticals

NCT04566549 COMPLETED

The Safety and Efficacy Evaluation of Hair Products Containing Probiotics

GenMont Biotech Incorporation

NCT02913157 COMPLETED

Hydroxychloroquine in Primary Progressive Multiple Sclerosis

University of Calgary

NCT04764383 WITHDRAWN

Histaminergic Basis of Fatigue in Multiple Sclerosis

University of Miami

NCT03518138 COMPLETED

Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor

Que Oncology

NCT02738775 COMPLETED

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

TG Therapeutics, Inc.

NCT02676544 TERMINATED

Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)

Rhode Island Hospital

NCT03152864 COMPLETED

Stabilizing Behavioral Rhythms to Improve Mental Health

HealthRhythms, Inc.

NCT02581384 TERMINATED

Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors

Dana-Farber Cancer Institute

NCT03033680 COMPLETED

Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA

Brigham and Women's Hospital

NCT02959658 COMPLETED

Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis

Rigshospitalet, Denmark

NCT02424396 COMPLETED

Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis

Assistance Publique - Hôpitaux de Paris

NCT03239860 TERMINATED

Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis

GeNeuro SA

NCT02782858 COMPLETED

Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS

GeNeuro SA

NCT02391961 COMPLETED

Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis

VA Office of Research and Development

NCT03500289 COMPLETED

Ketamine for Treatment of MS Fatigue

Johns Hopkins University

NCT02710214 COMPLETED

A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis

University of California, San Francisco

NCT02748317 COMPLETED

Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB

Medstar Health Research Institute

NCT02748356 COMPLETED

Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB

Medstar Health Research Institute

NCT03091400 COMPLETED

Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)

Icahn School of Medicine at Mount Sinai

NCT03326505 COMPLETED

Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment

University of Jordan

NCT02239393 COMPLETED

Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study

Ottawa Hospital Research Institute

NCT02308137 COMPLETED

Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)

University of Calgary

NCT03387046 TERMINATED

A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)

Merck KGaA, Darmstadt, Germany

NCT02609607 TERMINATED

Treating Anorectal Dysfunction in MS

David Levinthal

NCT02495766 COMPLETED

Autologous Mesenchymal Stromal Cells for Multiple Sclerosis

Banc de Sang i Teixits

NCT03183869 TERMINATED

Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

NCT03552263 COMPLETED

Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Tasly Pharmaceuticals, Inc.

NCT03000127 WITHDRAWN

Testosterone for Fatigue in Men With MS

University of California, Los Angeles

NCT03740295 COMPLETED

Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis

Fundación Universidad Católica de Valencia San Vicente Mártir

NCT02493049 COMPLETED

Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)

University of Calgary

NCT02545959 COMPLETED

Intrathecal Rituximab in Progressive Multiple Sclerosis

Centre Hospitalier de PAU

NCT02829827 TERMINATED

A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)

UCB Biopharma S.P.R.L.

NCT02689336 WITHDRAWN

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Washington University School of Medicine

NCT02569307 COMPLETED

Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States

Pakistan Institute of Living and Learning

NCT02166021 COMPLETED

Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis

Dimitrios Karussis

NCT02653417 TERMINATED

Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

Radius Pharmaceuticals, Inc.

NCT03403777 COMPLETED

Avelumab in Refractory Testicular Germ Cell Cancer.

National Cancer Institute, Slovakia

NCT02403947 TERMINATED

MEsenchymal StEm Cells for Multiple Sclerosis

University Hospital, Toulouse

NCT02686788 COMPLETED

TMP001 in Relapsing-remitting Multiple Sclerosis

Dr. Frank Behrens

NCT02551731 TERMINATED

Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

INSYS Therapeutics Inc

NCT03150966 COMPLETED

The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients

Tabriz University of Medical Sciences

NCT02542787 COMPLETED

Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis

Canbex Therapeutics Ltd

NCT02638038 COMPLETED

This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years

InteKrin Therapeutics, Inc.

NCT03223519 COMPLETED

COMBOPROFEN for Treatment of Muscular Pain Associated With Delayed Onset Muscle Soreness (DOMS)

Spherium Biomed

NCT02410200 COMPLETED

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS

Biogen

NCT02388295 COMPLETED

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

AstraZeneca

NCT02427776 TERMINATED

A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis

Imcyse SA

NCT02072252 WITHDRAWN

Mobile Phone App for Depression and Anxiety in Young Men Who Are Attracted to Men

Northwestern University

NCT02471222 COMPLETED

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Adamas Pharmaceuticals, Inc.

NCT02097849 COMPLETED

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

Biogen

NCT01649050 WITHDRAWN

Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis

Novartis Pharmaceuticals

NCT02170779 COMPLETED

Developing and Testing a Comprehensive MS Spasticity Management Program

VA Office of Research and Development

NCT02306811 TERMINATED

Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839

Genzyme, a Sanofi Company

NCT02011451 WITHDRAWN

Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis

Louisiana State University Health Sciences Center in New Orleans

NCT02418325 TERMINATED

A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

Genesis Limited

NCT03816345 RECRUITING

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

National Cancer Institute (NCI)

NCT05849467 RECRUITING

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

National Institute of Neurological Disorders and Stroke (NINDS)

NCT05704361 RECRUITING

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

Hoffmann-La Roche

NCT07139743 RECRUITING

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

Autolus Limited

NCT06138132 RECRUITING

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Stanford University

NCT07439029 NOT YET RECRUITING

YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases

Children's Hospital of Fudan University

NCT03759522 RECRUITING

Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

University of Alabama at Birmingham

NCT07148050 RECRUITING

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

Seattle Children's Hospital

NCT06220201 RECRUITING

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

NCT06436742 RECRUITING

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

argenx

NCT06700811 RECRUITING

Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

Heather Olson

NCT07224373 RECRUITING

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

AstraZeneca

NCT07172958 RECRUITING

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

Children's National Research Institute

NCT06451159 ACTIVE NOT RECRUITING

A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Bruce Cree

NCT07304154 NOT YET RECRUITING

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Kite, A Gilead Company

NCT07361094 RECRUITING

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Beijing Boren Hospital

NCT04377932 ACTIVE NOT RECRUITING

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Baylor College of Medicine

NCT07008378 RECRUITING

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

Genentech, Inc.

NCT07341828 NOT YET RECRUITING

A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy

Huashan Hospital

NCT06592703 RECRUITING

Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis

Rennes University Hospital

NCT06261528 ENROLLING BY INVITATION

Study of Circadian Focused Light Therapy in Progressive Multiple Sclerosis

University of Texas Southwestern Medical Center

NCT07289477 NOT YET RECRUITING

A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy

iRegene Therapeutics Co., Ltd.

NCT07270120 NOT YET RECRUITING

Senolytics for Secondary Progressive MS

Ohio State University

NCT06136819 ACTIVE NOT RECRUITING

RT-310 Dose Escalation BPH Study

Resurge Therapeutics Inc.

NCT04483778 ACTIVE NOT RECRUITING

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Seattle Children's Hospital

NCT03618381 ACTIVE NOT RECRUITING

EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Seattle Children's Hospital

NCT06198296 RECRUITING

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Baylor College of Medicine

NCT07221799 NOT YET RECRUITING

OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis

University of Maryland, Baltimore

NCT04897321 RECRUITING

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

St. Jude Children's Research Hospital

NCT06112093 RECRUITING

Repetitive Transcranial Magnetic Stimulation for Post-concussion Headaches

State University of New York - Upstate Medical University

NCT05620940 RECRUITING

A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.

Inventage Lab., Inc.

NCT05539729 RECRUITING

Vancomycin Study in Multiple Sclerosis (MS)

Icahn School of Medicine at Mount Sinai

NCT07141251 RECRUITING

Clinical Trial of BAO-G Technique in Complex Aortic Aneurysm Endovascular Repair (BAO-G-02)

Peking Union Medical College Hospital

NCT03783416 RECRUITING

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

Queen Mary University of London

NCT05755061 ACTIVE NOT RECRUITING

WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis

Kessler Foundation

NCT04572451 RECRUITING

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Yana Najjar

NCT07090889 RECRUITING

Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome.

Kamari Pharma Ltd

NCT06249438 RECRUITING

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

RenJi Hospital

NCT05103631 RECRUITING

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

Baylor College of Medicine

NCT06430671 ACTIVE NOT RECRUITING

Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

Cellerys AG

NCT06566261 ACTIVE NOT RECRUITING

ABA-101 in Participants With Progressive Multiple Sclerosis

Abata Therapeutics

NCT06869278 RECRUITING

A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT07001592 RECRUITING

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

NCT06999434 RECRUITING

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

Yale University

NCT04715191 RECRUITING

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Baylor College of Medicine

NCT06190912 ACTIVE NOT RECRUITING

Safety of Bryostatin in Patients With MS

Robert Fox

NCT05003388 RECRUITING

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS

The Foundation for Orthopaedics and Regenerative Medicine

NCT06900192 NOT YET RECRUITING

A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis

Stanford University

NCT04699747 RECRUITING

Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects

Massachusetts General Hospital

NCT02912897 RECRUITING

Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis

Nantes University Hospital

NCT05698017 ACTIVE NOT RECRUITING

Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)

Cytora Ltd.

NCT04046445 ACTIVE NOT RECRUITING

Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

Amal Therapeutics

NCT04789915 RECRUITING

Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis

Bjorn H. Ebdrup

NCT06552611 RECRUITING

Non-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis

University of Washington

NCT06518876 NOT YET RECRUITING

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

NCT05832515 RECRUITING

AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis

St. Petersburg State Pavlov Medical University

NCT06122181 RECRUITING

Study of HS-10384 in Participants of Chinese Postmenopausal Women

Hansoh BioMedical R&D Company

NCT04956744 RECRUITING

A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis

ImStem Biotechnology

NCT02511028 COMPLETED

In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging

National Institute of Neurological Disorders and Stroke (NINDS)

NCT03807973 SUSPENDED

Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.

University of Alabama at Birmingham

NCT03594487 TERMINATED

Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis

Jeffrey Gelfand

NCT04902313 COMPLETED

Cultivating Resilience in Oncology Practice

Linkoeping University

NCT07229404 COMPLETED

A Study to Investigate Relative Bioavailability, Safety and Tolerability of Single- and Multiple-doses of Elinzanetant in Healthy Female Participants

Bayer

NCT04943289 COMPLETED

Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis

Joanne Kurtzberg, MD

NCT02803268 COMPLETED

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms

Tanabe Pharma Corporation

NCT04272034 TERMINATED

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Incyte Corporation

NCT04171310 COMPLETED

Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects

Sanofi

NCT06064539 COMPLETED

Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects

Sanofi

NCT06683612 COMPLETED

PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF

Contineum Therapeutics

NCT04242199 COMPLETED

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Incyte Corporation

NCT05071729 COMPLETED

A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally

Bayer

NCT03972306 COMPLETED

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

Hoffmann-La Roche

NCT04602390 COMPLETED

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

Anokion SA

NCT04040231 COMPLETED

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Memorial Sloan Kettering Cancer Center

NCT06677710 SUSPENDED

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

Indapta Therapeutics, INC.

NCT05064436 TERMINATED

A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

Bristol-Myers Squibb

NCT05131971 COMPLETED

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants

GlaxoSmithKline

NCT06117020 COMPLETED

Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals

Motric Bio

NCT06204250 COMPLETED

A Study to Assess Safety and Tolerability of GS1-144 in Healthy Volunteers

Changchun GeneScience Pharmaceutical Co., Ltd.

NCT05853835 COMPLETED

First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641

LAPIX Therapeutics Inc.

NCT02618902 COMPLETED

A "negative"dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial

University Hospital, Antwerp

NCT05418426 COMPLETED

A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women

Daré Bioscience, Inc.

NCT06437262 COMPLETED

Antibacterial Effect and Substantivity of a New Chlorhexidine and Cymenol Gel on Oral Biofilm and Saliva

University of Santiago de Compostela

NCT06293326 COMPLETED

A First-in-Human Study to Learn How Well a Bi-Layer Calcium Carbonate Antacid Tablet Works Compared to a Standard, Non-Layered Calcium Carbonate Tablet in Healthy Male Participants

Bayer

NCT04284761 COMPLETED

A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

Alessa Therapeutics Inc.

NCT06429085 COMPLETED

Rex Robot Assisted Rehabilitation to Enhance Balance and Mobility for People With Multiple Sclerosis, Clinical and Biomarker Study - RAPPER IV

East Kent Hospitals University NHS Foundation Trust

NCT06219902 COMPLETED

A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women

Bayer

NCT06360861 COMPLETED

Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis

Tehran University of Medical Sciences

NCT05321602 COMPLETED

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Luye Pharma Group Ltd.

NCT03745144 COMPLETED

Effects of Cladribine Tablets on the PK of Microgynon®

Merck KGaA, Darmstadt, Germany

NCT05102682 COMPLETED

Robotics for Mobility Rehabilitation in MS

East Kent Hospitals University NHS Foundation Trust

NCT05983939 COMPLETED

Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers

Contineum Therapeutics

NCT05375825 WITHDRAWN

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

National Cancer Institute (NCI)

NCT02482168 COMPLETED

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Apexigen America, Inc.

NCT04203017 TERMINATED

Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis

St. Petersburg State Pavlov Medical University

NCT03749967 COMPLETED

rTMS for Emotional Difficulties in Verterans

VA Office of Research and Development

NCT06106074 COMPLETED

Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants

Sanofi

NCT02536183 TERMINATED

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors

AeRang Kim

NCT04889287 COMPLETED

A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants

Bayer

NCT04845841 COMPLETED

Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body

Bayer

NCT05481528 COMPLETED

A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants

Bayer

NCT04922593 COMPLETED

Relative Bioavailability of LY03010 Compared to Listed Drug

Luye Pharma Group Ltd.

NCT05790902 COMPLETED

COMPARISON OF SILODOSIN AND TAMSULOSIN IN MEDICAL EXPULSIVE THERAPY OF DISTAL URETERIC CALCULI

Armed Forces Institute of Urology, Rawalpindi

NCT03775850 COMPLETED

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Evelo Biosciences, Inc.

NCT05432713 COMPLETED

A Study of LP-168 in Healthy Volunteers

Guangzhou Lupeng Pharmaceutical Company LTD.

NCT03656627 TERMINATED

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

Alliance Foundation Trials, LLC.

NCT04990219 TERMINATED

A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis

H. Lundbeck A/S

NCT04570670 COMPLETED

Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects

Banner Life Sciences LLC

NCT05471817 COMPLETED

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

Bayer

NCT04941781 COMPLETED

PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers

Contineum Therapeutics

NCT04489420 TERMINATED

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

Celularity Incorporated

NCT05381142 COMPLETED

A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years

Bayer

NCT05351892 COMPLETED

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

Bayer

NCT03274804 COMPLETED

Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC

University Hospital Heidelberg

NCT04982991 COMPLETED

Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants

Sanofi

NCT02977533 COMPLETED

A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis

Sanofi

NCT04981431 COMPLETED

A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female Adults

Bayer

NCT04903821 COMPLETED

A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female Participants

Bayer

NCT05061563 COMPLETED

A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults

Bayer

NCT05029609 WITHDRAWN

Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS

Tiziana Life Sciences LTD

NCT05028608 COMPLETED

A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.

Bayer

NCT02982941 COMPLETED

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

MacroGenics

NCT05181215 COMPLETED

Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects

Banner Life Sciences LLC

NCT03652077 COMPLETED

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Incyte Corporation

NCT04725175 COMPLETED

Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers

Contineum Therapeutics

NCT03551275 COMPLETED

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

Biocad

NCT03269071 COMPLETED

Neural Stem Cell Transplantation in Multiple Sclerosis Patients

IRCCS San Raffaele

NCT03282760 COMPLETED

Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients

Casa Sollievo della Sofferenza IRCCS

NCT03122912 TERMINATED

Explore Effects of Dietary Fish Oil in Human Skin

University of Michigan

NCT02583594 COMPLETED

A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis

Genzyme, a Sanofi Company

NCT02312986 COMPLETED

FMT for Multidrug Resistant Organism Reversal

Washington University School of Medicine

NCT02939859 WITHDRAWN

Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions

Healeon Medical Inc

NCT04635709 COMPLETED

Effect of Behavioral Therapy Versus Interferential Current on Bladder Dysfunction in Patients With Multiple Sclerosis

Taibah University

NCT03699722 COMPLETED

A Women-Focused PrEP Intervention

University of Pennsylvania

NCT03574428 COMPLETED

Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers

GeNeuro Australia PTY Ltd

NCT03266965 COMPLETED

Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach

University of Miami

NCT02390843 COMPLETED

Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors

Emory University

NCT02283671 COMPLETED

Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B

Sara Varea

NCT04022473 COMPLETED

Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers

Banner Life Sciences LLC

NCT03005002 COMPLETED

Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

City of Hope Medical Center

NCT02423083 TERMINATED

Oral Guanabenz for Multiple Sclerosis

National Institute of Neurological Disorders and Stroke (NINDS)

NCT03493841 COMPLETED

Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis

Rebecca Spain

NCT01957683 WITHDRAWN

Canadian eCLIPs™ Safety and Feasibility Study Protocol

Evasc Medical Systems Corp.

NCT03138421 COMPLETED

Central Pain Study for ABX-1431

Abide Therapeutics

NCT02760056 COMPLETED

Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study

Oregon Health and Science University

NCT02398461 COMPLETED

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

Acorda Therapeutics

NCT02601885 COMPLETED

A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

AbbVie

NCT02797015 COMPLETED

Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS

Celgene

NCT02506751 COMPLETED

Open-label Study of Liothyronine in MS

Johns Hopkins University

NCT02164097 TERMINATED

ODSH + ICE Chemotherapy in Pediatric Solid Tumors

New York Medical College

NCT03107013 COMPLETED

A Study to Investigate the Mass Balance of BTD-001

Balance Therapeutics

NCT03237832 COMPLETED

A Phase 1 Study of ARN-6039

Arrien Pharmaceuticals

NCT02606630 TERMINATED

[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis

AbbVie

NCT02833142 COMPLETED

Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes

Biogen

NCT02641041 COMPLETED

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants

Biogen

NCT02882724 COMPLETED

Changes in Speed, Endurance and Balance in Women Patients With Multiple Sclerosis After 4 & 8 Weeks of Aquatic Exercise Training

University of Isfahan

NCT02494349 COMPLETED

The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.

Jeil Pharmaceutical Co., Ltd.

NCT02764372 COMPLETED

Telerehabilitation Upper Extremity for Neurological Disorders

Fondazione Don Carlo Gnocchi Onlus

NCT02474134 COMPLETED

Comparison Study of PF530 and Betaferon in Healthy Subjects

Pfenex, Inc

NCT02521545 COMPLETED

Single-Dose Study of a New Formulation of BIIB061

Biogen

NCT04480853 RECRUITING

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Novartis Pharmaceuticals

NCT07087912 NOT YET RECRUITING

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

University of Sao Paulo General Hospital

NCT06136728 RECRUITING

Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

MGH Institute of Health Professions

NCT06444113 RECRUITING

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

Novartis Pharmaceuticals

NCT07389590 NOT YET RECRUITING

Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

Johns Hopkins University

NCT04387734 ACTIVE NOT RECRUITING

Effects of Ocrevus in Relapsing Multiple Sclerosis

Georgia State University

NCT07376148 RECRUITING

Fractional CO2 Laser-assisted Delivery of Hyaluronic Acid, Ascorbic Acid and Sodium DNA For Enhancing Facial Skin Quality in Individuals Over the Age of 30

Instituto de Oftalmología Fundación Conde de Valenciana

NCT07372612 NOT YET RECRUITING

Flow-diverting Devices for the Treatment of Middle Cerebral Artery Bifurcation Aneurysms

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT05090371 ACTIVE NOT RECRUITING

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Novartis Pharmaceuticals

NCT04466150 ACTIVE NOT RECRUITING

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

University of California, San Francisco

NCT07353749 NOT YET RECRUITING

Efficacy and Safety of Methylprednisolone After Flow-Diverter Stent Implantation in Unruptured Intracranial Aneurysms

Duan Chuanzhi

NCT05285891 RECRUITING

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT07087106 RECRUITING

Glucose Consumption in MS Using [F-18]FDG-PET

Brigham and Women's Hospital

NCT07240649 NOT YET RECRUITING

Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications

Jay C. Buckey Jr.

NCT07308002 NOT YET RECRUITING

Intermittent vs Daily Tamsulosin for LUTS/BPH

Mansoura University

NCT07303582 RECRUITING

Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities

Oxford University Hospitals NHS Trust

NCT07225361 RECRUITING

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Northwestern University

NCT07276919 NOT YET RECRUITING

Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy

Peking University First Hospital

NCT04178005 ACTIVE NOT RECRUITING

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

University of Texas Southwestern Medical Center

NCT04289142 RECRUITING

Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients

Sunnybrook Health Sciences Centre

NCT06733922 RECRUITING

ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

Novartis Pharmaceuticals

NCT06529406 RECRUITING

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

University of Colorado, Denver

NCT04601233 NOT YET RECRUITING

Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis

Tulane University

NCT03535298 ACTIVE NOT RECRUITING

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

The Cleveland Clinic

NCT07138833 NOT YET RECRUITING

A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS)

Qilu Pharmaceutical (Hainan) Co., Ltd.

NCT02670161 ENROLLING BY INVITATION

Quality Improvement and Practice Based Research in Neurology Using the EMR

Endeavor Health

NCT07118462 RECRUITING

HighCycle Study: Acetazolamide, High Altitude and Plasma Volume

Centre d'Expertise sur l'Altitude EXALT

NCT06951906 RECRUITING

Imaging Biomarkers of FOG Response to DBS

Medical University of South Carolina

NCT04297592 ENROLLING BY INVITATION

Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

Mayo Clinic

NCT06396039 ACTIVE NOT RECRUITING

A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

Bristol-Myers Squibb

NCT05465031 RECRUITING

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Silesian Centre for Heart Diseases

NCT06838559 ACTIVE NOT RECRUITING

Clinical Trial on 7-day Followed by Maintenance Therapy for 10 Weeks vs. 14-day and no Maintenance Course of Prednisolone for the Treatment of Infantile Epileptic Spasms Syndrome (IESS)

University of Colombo

NCT06495593 RECRUITING

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

University of California, San Francisco

NCT04245436 RECRUITING

Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)

University of Cincinnati

NCT06486363 NOT YET RECRUITING

Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT06171906 NOT YET RECRUITING

Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation

ShiCang Yu

NCT05296161 RECRUITING

B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis

Amsterdam UMC, location VUmc

NCT04650321 RECRUITING

Home Based Infusions for Ocrelizumab

University of Colorado, Denver

NCT05084638 COMPLETED

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

Novartis Pharmaceuticals

NCT04377555 COMPLETED

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

Genentech, Inc.

NCT04998851 COMPLETED

A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

Hoffmann-La Roche

NCT05199571 COMPLETED

Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

Novartis Pharmaceuticals

NCT04667949 COMPLETED

Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients

Novartis Pharmaceuticals

NCT04230174 COMPLETED

Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation

Massachusetts General Hospital

NCT04952766 COMPLETED

Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults

Centre Hospitalier Régional d'Orléans

NCT03610815 COMPLETED

Community I-STAR Mozambique: Community Implementation of SBIRT Using Technology for Alcohol Use Reduction in Mozambique

New York State Psychiatric Institute

NCT04410965 COMPLETED

Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks

Sanofi

NCT04677491 COMPLETED

Effects of Ospemifene on Brain Activation Patterns in Women With Sexual Interest-arousal Disorders

Hospital Clinic of Barcelona

NCT04998812 COMPLETED

A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

Hoffmann-La Roche

NCT05415748 COMPLETED

Deprescribing Tamsulosin in Older Men

University of California, San Francisco

NCT06266000 COMPLETED

Comparison of 2 Extracts of Saw Palmetto Versus Placebo on Lower Urinary Tract Symptoms (LUTS) and Urinary Frequency

RDC Clinical Pty Ltd

NCT03963375 COMPLETED

Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis

Washington University School of Medicine

NCT05658484 COMPLETED

A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

Biogen

NCT04869358 COMPLETED

Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab

Novartis Pharmaceuticals

NCT04878211 TERMINATED

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Novartis Pharmaceuticals

NCT06508944 COMPLETED

Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women

Mahidol University

NCT03646292 COMPLETED

Antidiabetic Drugs for Steatotic Liver Disease

Yonsei University

NCT04261790 COMPLETED

Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

Johns Hopkins University

NCT03853746 COMPLETED

Short-term B-cell Depletion in Relapsing Multiple Sclerosis

Johns Hopkins University

NCT03110315 COMPLETED

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

Theodore R. Brown, MD MPH

NCT03046251 COMPLETED

Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis

State University of New York at Buffalo

NCT04783935 COMPLETED

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

NCT05777902 TERMINATED

Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.

I.R.C.C.S. Fondazione Santa Lucia

NCT06613243 COMPLETED

Different Doses of Dexmedetomidine Combined With Esketamine in Women Undergoing Cesarean Delivery

Peking University First Hospital

NCT04807517 COMPLETED

Buspirone Treatment of Anxiety in Williams Syndrome

Massachusetts General Hospital

NCT03750656 TERMINATED

Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation

University of Kansas Medical Center

NCT04877457 TERMINATED

Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.

Yale University

NCT04667117 COMPLETED

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Novartis Pharmaceuticals

NCT04819360 TERMINATED

Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis

Brigitte Schürch

NCT03557294 COMPLETED

Varenicline OTC Trial on Efficacy and Safety

Arizona State University

NCT05657860 COMPLETED

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

Maimonides Medical Center

NCT06334094 WITHDRAWN

Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS

The University of Texas at Dallas

NCT05532163 TERMINATED

A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Biogen

NCT04792567 COMPLETED

Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)

Novartis Pharmaceuticals

NCT05615948 COMPLETED

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

Maimonides Medical Center

NCT04776213 COMPLETED

Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

NCT06310642 COMPLETED

Efficacy of Prophylactic Treatment of Oral Prochlorperazine for Acute Mountain Sickness

CHRISTUS Health

NCT03021317 TERMINATED

Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses

University of Chicago

NCT05177718 TERMINATED

Natalizumab and Chronic Inflammation

Vanderbilt University Medical Center

NCT05603403 COMPLETED

Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms

Azidus Brasil

NCT03817931 COMPLETED

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

Baylor Research Institute

NCT05208840 WITHDRAWN

A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis

Hoffmann-La Roche

NCT03961204 COMPLETED

Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)

EMD Serono Research & Development Institute, Inc.

NCT03369665 COMPLETED

Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)

Merck KGaA, Darmstadt, Germany

NCT02549573 TERMINATED

Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®

MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

NCT02587065 COMPLETED

Plegridy Satisfaction Study in Participants

Biogen

NCT03073603 COMPLETED

Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)

University of Colorado, Denver

NCT05883332 COMPLETED

A Pilot Study to Assess Effects of Self-Administered Nitrous Oxide (SANO) on Urodynamic Study (UDS) Parameters

Beth Israel Deaconess Medical Center

NCT03856619 COMPLETED

To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis

Sanofi

NCT03364036 COMPLETED

Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)

Merck KGaA, Darmstadt, Germany

NCT03621761 COMPLETED

Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue

University of Michigan

NCT04129736 COMPLETED

Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis

Jan Lycke

NCT02739542 COMPLETED

Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)

University of Texas Southwestern Medical Center

NCT03544268 COMPLETED

Academic-Industrial Partnership for Translation of Acoustic Angiography

UNC Lineberger Comprehensive Cancer Center

NCT03784898 COMPLETED

Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

Genzyme, a Sanofi Company

NCT02255656 COMPLETED

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

Genzyme, a Sanofi Company

NCT03135249 COMPLETED

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis

University of Texas Southwestern Medical Center

NCT03589105 COMPLETED

A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting

Hoffmann-La Roche

NCT02499900 COMPLETED

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

Teva Branded Pharmaceutical Products R&D, Inc.

NCT02419378 COMPLETED

Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential

University Hospital Muenster

NCT03257358 COMPLETED

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

Novartis Pharmaceuticals

NCT02471560 COMPLETED

Tecfidera and the Gut Microbiota

Biogen

NCT03126760 TERMINATED

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

Mallinckrodt ARD LLC

NCT02252367 COMPLETED

Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms

University of Florence

NCT02446886 TERMINATED

Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS

Weill Medical College of Cornell University

NCT03177083 COMPLETED

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

Biogen

NCT02904876 TERMINATED

Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis

University Hospital, Strasbourg, France

NCT02410278 COMPLETED

Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera

Biogen

NCT04238208 COMPLETED

The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Males With Diabetic Neuropathy

Corporacion Parc Tauli

NCT03345940 TERMINATED

Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

NCT02373098 COMPLETED

Fingolimod Effect on Cytokine and Chemokine Levels

Novartis Pharmaceuticals

NCT03516526 COMPLETED

Towards Personalized Dosing of Natalizumab in Multiple Sclerosis

Amsterdam UMC, location VUmc

NCT03269175 COMPLETED

BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies

Bayer

NCT02079818 WITHDRAWN

Visceral Artery Aneurysm Embolization by the Penumbra Ruby™ Coil System

Penumbra Inc.

NCT03385356 COMPLETED

Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis

University Medical Centre Maribor

NCT03856242 COMPLETED

Benign Prostatic Hyperplasia and Ischemic Heart DIsease

I.M. Sechenov First Moscow State Medical University

NCT02720107 COMPLETED

Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)

Novartis Pharmaceuticals

NCT03007121 COMPLETED

Intrathecal Morphine Analgesia vs. Continuous Epidural Analgesia vs. Systemic Analgesia in Colorectal Surgery.

Charles University, Czech Republic

NCT02901106 TERMINATED

Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate

Fondation Ophtalmologique Adolphe de Rothschild

NCT02461069 COMPLETED

Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis

University Hospital Muenster

NCT03091569 COMPLETED

Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy

Biogen

NCT02665221 TERMINATED

Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY

NYU Langone Health

NCT03194594 COMPLETED

Dexamethasone and Ketamine on Change of Postoperative Mood

Wonkwang University Hospital

NCT02343159 TERMINATED

Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.

Biogen

NCT02807220 COMPLETED

Efficacy and Safety of Imuneks 10 mg Capsules in the Prophylaxis of Cold

Imuneks Farma ilac San. Tic. A.S.

NCT02683863 COMPLETED

Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers

Multiple Sclerosis Center of Northeastern New York

NCT02675413 WITHDRAWN

Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS

Washington University School of Medicine

NCT02568111 WITHDRAWN

Brimonidine Tartrate for the Treatment of Injection Related Erythema

Biogen

NCT02472938 WITHDRAWN

Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis

Biogen

NCT02090348 WITHDRAWN

Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate

Biogen

Data: ClinicalTrials.gov